Donanemab (LY3002813) is a humanized IgG1kappa monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Abeta) epitope. Donanemab has the potential for early Alzheimers disease research.
Purity:
>99.0%
CAS Number:
[1931944-80-7]
Target:
Amyloid
* VAT and and shipping costs not included. Errors and price changes excepted